Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Trevena Inc. Stories

2013-10-15 08:31:22

KING OF PRUSSIA, Pa., Oct. 15, 2013 /PRNewswire/ -- Trevena, Inc. (Trevena), a clinical stage pharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the electronic publication of the first clinical manuscript of its lead CNS asset, TRV130. The manuscript entitled, "First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers." can be viewed online at the Journal of Clinical...

2013-10-10 08:28:45

KING OF PRUSSIA, Pa., Oct. 10, 2013 /PRNewswire/ -- Trevena, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Trevena has applied to list its common stock on the NASDAQ Global Market under the ticker symbol "TRVN."...

2013-09-17 12:30:01

KING OF PRUSSIA, Pa., Sept. 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced the appointment of Roberto Cuca as senior vice president and chief financial officer. "We are delighted to have Roberto join Trevena at this pivotal juncture in the company's development," said Maxine Gowen, Ph.D., president and chief executive officer...

2013-07-30 08:33:11

KING OF PRUSSIA, Pa., July 30, 2013 /PRNewswire/ -- Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today the publication of new findings related to the mechanism of action of its Angiotensin II Type 1 Receptor (AT1R) biased ligands. The publication describes work led by R. John Solaro PhD, Distinguished University Professor and Head of the Department of Physiology and Biophysics at the University of Illinois at Chicago,...

2013-07-17 08:25:33

Patent coverage granted until 2031 for Trevena's lead Phase 2 compound in acute heart failure KING OF PRUSSIA, Pa., July 17, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that the United States Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027. United States...

2013-07-08 08:26:28

KING OF PRUSSIA, Pa., July 8, 2013 /PRNewswire/ -- Trevena, Inc. (Trevena), a clinical stage pharmaceutical company and the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced the electronic publication of Trevena's manuscript, "First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers." The manuscript can be viewed online at the Journal of Clinical Pharmacology's website...

2013-05-09 08:29:44

Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate KING OF PRUSSIA, Pa. and NEW YORK, May 9, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories Holding Limited (Forest), a subsidiary of Forest Laboratories Inc. (NYSE: FRX), an international pharmaceutical company,...

2013-04-22 08:30:15

KING OF PRUSSIA, Pa., April 22, 2013 /PRNewswire/ -- Trevena, Inc. a clinical stage pharmaceutical company today announced that its President and CEO, Dr. Maxine Gowen will present at the 12th Annual Needham Healthcare Conference on May 1, 2013, 10:00am, at Grand Hyatt New York. Dr. Gowen will provide a detailed overview of the company's most advanced clinical programs which include TRV027, a biased ligand for the treatment of acute heart failure, which is currently in Phase 2 studies, and...

2013-01-07 08:28:42

WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases. Under the terms of the...

2008-09-25 09:00:54

Dr. Robert Lefkowitz has been awarded the National Medal of Science for his contribution to biology, and will receive the award from President Bush at a White House ceremony on Monday September 29th. Dr. Lefkowitz, 65, who is currently an Investigator of the Howard Hughes Medical Institute and James B. Duke Professor of Medicine and Biochemistry at Duke University Medical Centre, has been recognized for his pioneering work understanding the G-protein coupled receptor system and its...